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Activating mutations in the gene encoding BRAF are the most commonly identified oncogenic abnormalities in papillary thyroid
cancer. In vitro and in vivo models have demonstrated that overexpression of activated BRAF induces malignant transformation and
aggressive tumour behaviour. BRAF and other RAF kinases are frequently activated by other thyroid oncogenes and are important
mediators of their biological effects including dedifferentiation and proliferation. Because current therapeutic options for patients with
thyroid cancers that are aggressive and/or do not respond to standard therapies are limited, BRAF and its downstream effectors
represent attractive therapeutic targets. In this review, data supporting a role for BRAF activation in thyroid cancer development and
establishing the potential therapeutic efficacy of BRAF-targeted agents in patients with thyroid cancer will be reviewed.
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Thyroid cancer incidence is increasing throughout the world.
Although this appears to be due largely to enhanced detection of
early thyroid cancers by the more generalised use of thyroid
ultrasound and fine-needle aspiration (Davies and Welch, 2006),
the number of patients who succumb to this disease is also rising
annually (Ries et al, 2006). Thyroid cancer therapy is based on a
three-pronged approach that includes thyroidectomy, and in more
aggressive cases, radioactive iodine therapy and suppression of
thyrotropin (TSH) levels using levothyroxine. This regimen
achieves outstanding long-term survival rates for most patients
with thyroid cancer, particularly for the majority diagnosed with
early-stage disease. However, for the subset of patients who do
not respond to this treatment paradigm, or who present with
aggressive primary tumours, therapeutic options are relatively
limited and long-term survival rates are low. Treatment using
cytotoxic chemotherapy has been largely unsuccessful and
although external beam radiation has been shown to be helpful
in palliation, cure is rarely achieved. Therefore, developing new
approaches to treating patients with aggressive and/or progressive
thyroid cancers is an important avenue of research that requires
identification of appropriate molecular therapeutic targets.
Over the past few years, it has become evident that aberrant
signalling through the RAS–RAF–MEK cascade is crucial for the
development of thyroid cancer. In the case of papillary thyroid
cancer (PTC), the subtype that accounts for more than 80% of
all thyroid cancers, mutations and/or gene rearrangements in cell
surface receptors or signalling molecules in this cascade occur in
B70% of cases and are tumorigenic in vitro and in vivo (reviewed
in Kondo et al, 2006). Of these abnormalities, activating mutations
in BRAF (V600E) are particularly common in adults with PTC,
accounting for approximately 45% of cases (reviewed in Xing
2005). Because BRAF is activated through multiple mechanisms in
the majority of thyroid cancers (see Figure 1), there has been an
interest in targeting BRAF for potential therapeutic benefit in
patients with thyroid cancer.
BRAF MUTATIONS IN PTC TUMORIGENESIS
The RAF kinases, termed ARAF, BRAF and CRAF, are essential
signalling serine–threonine kinase proteins in the RAS-RAF-MEK-
ERK cascade (Figure 1). In vitro studies in benign thyroid cell
models have demonstrated a particularly important role for
BRAF, in comparison to other RAF isoforms, as a central regulator
of thyroid-specific protein expression (i.e., differentiation) and
proliferative capacity (Mitsutake et al, 2005a). The discovery that
mutations in BRAF resulting in constitutive kinase activation are
common occurrences in solid tumours (Davies et al, 2002) led a
number of groups to analyse thyroid cancers for similar mutations
in BRAF. In total, mutations that result in a V600E substitution in
BRAF and consequent constitutive activation occur in approxi-
mately 45% of PTCs in adults, making BRAF mutations the most
common defined genetic abnormality in thyroid cancers (Xing,
2005). In addition to the V600E mutation, rare thyroid tumours
have been described with mutations at the 599 and 601 locations
that also result in constitutive activation of BRAF kinase (Trovisco
et al, 2004; Moretti et al, 2006E). It has recently been recognised
that rearrangements involving BRAF and AKAP9 that result in
increased BRAF signalling occur in a small subset of PTCs (Ciampi
et al, 2005). Thus, taken together, direct oncogenic activation of
BRAF is an extremely common event in PTC tumorigenesis.
In addition to BRAF mutations, gene rearrangements resulting
in constitutive activation of the tyrosine kinase receptor, RET
(RET/PTC oncogenes) that activate the RAS–RAF–MEK and
other signalling cascades are common in PTC (Figure 1). These
rearrangements, in addition to the AKAP9/BRAF rearrangements
and rearrangements involving the NTRK oncogene, are associated
with PTCs that develop following radiation exposure. Activation of
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histologically characterised as PTCs, as activating mutations in
RAS genes (particularly N-RAS) occur in 20–30% of follicular
thyroid cancers (FTCs) as well as in a smaller percentage of
potentially premalignant follicular adenomas (Vasko et al, 2003).
Interestingly, PTCs that have a follicular growth pattern (follicular
variant of PTC) also frequently have activating mutations in RAS
oncogenes (Zhu et al, 2003; Adeniran et al, 2006). Therefore,
increased RAF kinase activity induced by activation of upstream
signalling molecules events is also common in thyroid cancer,
further accentuating the broad importance of this family of
signalling molecules in thyroid tumorigenesis.
Functionally, BRAF V600E is capable of inducing thyroid cell
transformation in vitro and to induce thyroid cancer in vivo in
transgenic mice with thyroid-specific expression of the protein
(Knauf et al, 2005). These data confirm that BRAF V600E is an
oncogene for thyroid cancer. Because BRAF and the other RAF
kinases were putative downstream signal transducing molecules
for RET/PTC, and because mutations in BRAF and RAS, and
rearrangements in NTRK and RET/PTC are largely mutually
exclusive in human PTC samples, it was suggested that the RAS/
RAF/MEK pathways might represent a linear cascade whose
activation promotes thyroid cancer formation (Kimura et al,
2003; Soares et al, 2003). To test this hypothesis, a series of elegant
gene expression studies were performed using in vitro models and
clinical samples to determine the role of BRAF in RET/PTC effects
in thyroid cells (Melillo et al, 2005; Mitsutake et al, 2005b) and the
degree of overlap in gene expression in tumours with either genetic
abnormality (Giordano et al, 2005). Taken together, these studies
demonstrate that BRAF and RET/PTC share similar mechanisms
for their acute effects on thyroid cells and that there is substantial,
although not complete overlap in gene expression profiles of
PTC expressing either oncogene. The relative importance of BRAF
signalling in the actions of the different RET/PTC or RAS
oncogenes has not yet been carefully dissected, although it seems
likely that BRAF, and perhaps other RAF kinases, play an
important role based on data from cell model systems.
Important distinctions between tumours that express RET/PTC
vs BRAF V600E are their relationships to radiation exposure and
age at PTC diagnosis. Convincing functional and epidemiologic
evidence supports the ability of radiation to induce RET/PTC gene
rearrangements and a high prevalence of RET/PTC expression in
radiation-induced PTCs (reviewed in Ciampi and Nikiforov, 2006).
In contrast, BRAF mutations appear to be uncommon in radiation-
related PTCs. In addition, RET/PTC is more prevalent in childhood
thyroid cancers, whereas BRAF V600E mutations are extremely
rare in children and the age of patients with PTCs who express
BRAF V600E is more than that of the general PTC population
(Xing et al, 2005; Ciampi and Nikiforov, 2006).
BRAF MUTATIONS IN AGGRESSIVE PTC
The relationship between the BRAF V600E mutation and
aggressive tumour behaviour is controversial. In several studies,
the presence of a BRAF V600E mutation has been associated with
a more aggressive clinical course (Namba et al, 2003; Nikiforova
et al, 2003; Xing et al, 2005; Riesco-Eizaguirre et al, 2006).
However, these results have not been confirmed in a number of
other studies (Fugazzola et al, 2004; Kim et al, 2005; Fugazzola
et al, 2006). This discrepancy may be related to study size, the
duration of follow-up, differences in histological designation of
tumours, and/or the specific populations analysed. Similarly,
although all studies associate the presence of a BRAF V600E
mutation with papillary architecture, several studies have reported
a higher prevalence of BRAF mutations in tumours classified as
tall cell or columnar cell variants of PTC that are associated with
more aggressive clinical behaviour and loss of responsiveness to
radioiodine (Nikiforova et al, 2003; Begum et al, 2004). However,
as noted above, an association between BRAF mutations and
aggressive tumour behaviour has not been demonstrated in all
populations, making the clinical relevance of this association
uncertain. It is also of interest that the incidence of BRAF V600E
mutations in undifferentiated anaplastic thyroid cancer is similar
to that in well-differentiated early-stage tumours in several studies
(Namba et al, 2003; Nikiforova et al, 2003; Begum et al, 2004;
Soares et al, 2004; Trovisco et al, 2004; Trovisco et al, 2005)
supporting the concept that some anaplastic thyroid cancers arise
from more typical forms of PTC and suggesting that BRAF
signalling may be functionally important in anaplastic thyroid
cancers. These data also suggest that BRAF mutations may not be
independently sufficient to induce dedifferentiation. Finally, it
has been proposed that detection of BRAF V600E might be used to
stratify patients for more aggressive initial therapy or to help
diagnose PTC on indeterminate fine-needle aspiration samples. In
fact, methods for rapid detection of this mutation on fine-needle
aspiration samples have been developed (Xing et al, 2004).
However, the true predictive nature of BRAF mutations for
aggressive behaviour, particularly when considering the high
frequency of BRAF mutations in small PTCs associated with an
excellent prognosis, remains uncertain.
The potential mechanisms by which BRAF mutations might
predispose PTCs to have a more aggressive course and/or poor
responsiveness to standard therapies are not certain. In vitro
studies in thyroid cells suggest that BRAF V600E induces invasion
via increased expression of matrix metalloproteinases (MMP12)
(Mesa et al, 2006) and that it reduces expression and membrane
localisation of the Na, I symporter responsible for thyrocyte uptake
of iodine (Riesco-Eizaguirre et al, 2006). The thyroid-specific
BRAF V600E mouse model also develops invasive and poorly
differentiated thyroid cancer that develops progressive local
invasion in association with markers of aggressive tumour
behaviour (Knauf et al, 2005). In human thyroid cancers, it has
recently been reported that BRAF V600E is highly associated with
(1) overexpression of VEGF and that overexpression of VEGF was
highly associated with increasing tumour stage and invasion (Jo
et al, 2006) and (2) reduced membrane expression of NIS (Riesco-
Eizaguirre et al, 2006). Thus, a combination of markers of
aggressive behaviour, perhaps including BRAF mutation status,
may be useful in improving predictions of tumour behaviour.
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Figure 1 Activation of the RAS–RAF–MEK pathway in thyroid cancer.
Constitutive activation via gene mutations or rearrangements in RET, RAS
and BRAF (highlighted in red) are the principal initiators of thyroid cancer
development through enhanced nuclear translocation of ERK and
subsequent transcriptional regulation of target genes. Activation of this
tumour initiation pathway occurs in B70% of thyroid cancers. Activation of
other pathways that cooperatively activate ERK, as well regulate other cell
signaling pathways may also be involved with ERK in thyroid cancer
progression. *Proteins known to be constitutively activated in thyroid
cancer.
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In comparison to BRAF mutations that occur at similar
frequencies in well-differentiated PTCs and undifferentiated
tumours, several events (Figure 1), including mutations in the
P53 gene and overactivation of the Wnt-signalling cascade occur
much more frequently in undifferentiated thyroid cancers (Kondo
et al, 2006). Whether enhanced RAF kinase activity influences
these later changes is an uncertain but important question when
considering BRAF and RAF kinases as therapeutic targets for
patients with undifferentiated forms of thyroid cancer.
BRAF AS A THERAPEUTIC TARGET FOR PTC
Preclinical studies
Because BRAF V600E expression is common in PTCs, it represents
a potentially important target for progressive PTC therapy. This
potential may not be limited to just PTCs with BRAF-activating
mutations because BRAF and the entire RAF kinase family are
activated by other oncogenes involved in thyroid cancer develop-
ment, in both PTC and follicular carcinomas (Figure 1). A number
of compounds have been designed to target RAF kinases at low
concentrations, with greater or lesser specificity. Several of these
have been tested in thyroid cancer models in vitro.
Molecular inhibition of BRAF specifically using siRNA has been
shown to inhibit proliferation of several different poorly differ-
entiated thyroid cancer cell lines, some of which express V600E
BRAF (Salvatore et al, 2006). These data, in concert with the
evidence described above that BRAF V600E overexpression
increases proliferation and DNA instability of thyroid cells and
the central role of BRAF as a critical signalling node in RET/PTC-
induced thyroid cell proliferation, suggest BRAF as an appropriate
therapeutic target for thyroid cancer.
Sorafenib is a bis-aryl urea (Nexavar, Bayer HealthCare
Pharmaceuticals, New Haven, CT, USA) competitive inhibitor of
all RAF isoforms, BRAF V600E, and several other tyrosine kinase
receptors, including KDR, PDGFR, KIT and RET at nanomolar
concentrations in vitro (Wilhelm et al, 2004). Several studies have
demonstrated the ability of this agent to inhibit proliferation of
poorly differentiated thyroid cancer cell lines with and without
BRAF V600E mutations in vitro (Ouyang et al, 2006; Salvatore
et al, 2006). In addition, Sorafenib has been shown to inhibit
growth and enhance apoptosis in one anaplastic thyroid cancer cell
line in xenograft models at micromolar concentrations that are
achievable in patients (Ouyang et al, 2006; Salvatore et al, 2006).
Whether the activity of Sorafenib in thyroid cancer is mediated by
inhibiting RAF kinases, RET or its other targets is uncertain. It is
of interest that other agents that inhibit VEGF activity specifically
have been shown to have salutary effects against thyroid cancer cell
lines in vitro and in vivo (Bauer et al, 2003). As described below
(see clinical studies section), Sorafenib is currently being evaluated
in patients with iodine non-responsive thyroid cancer.
Two additional potent isoquinoline RAF kinase inhibitors, NVP-
AAL881-NX and NVP-LBT613-AG-8 (Novartis, Cambridge, MA,
USA), have been tested in vitro and in vivo against a panel of
poorly differentiated thyroid cancer cell lines (Ouyang et al, 2006).
Both agents inhibit proliferation and induce cell death in thyroid
cancer cell in micromolar concentrations, although there was
variable resistance to these effects among the cell lines. In vivo,
both agents inhibited xenograft growth, although some toxicity
was reported at higher doses with NVP-LBT613-AG-8. Similar to
Sorafenib, these compounds inhibit KDR function and it is of
interest that the effects in vivo did not correlate with inhibition of
RAF activity for one of the cell lines, further suggesting that several
targets may be therapeutically important in progressive thyroid
cancer.
A number of additional compounds targeted to inhibit RAF
kinases are in development that vary in their designs and
specificity (Thompson and Lyons, 2005). Preclinical data suggest
that inhibition of RAF kinase activity, alone or in combination
with other effects, may have therapeutic benefit. It should be noted
that there are a number of other studies using kinase inhibitors
that do not have appreciable effects on RAF kinases. Preclinical
and clinical data using these agents are not addressed in this mini
review; however, they support the notion that inhibition of thyroid
cancer cells at multiple targets may be therapeutically advanta-
geous (Braga-Basaria and Ringel, 2003).
The potential enthusiasm that targeting the linear RAS–RAF–
MEK–ERK cascade in patients with thyroid with different
oncogenic alterations must be reconciled with the recent data of
Solit et al (2006) who examined the response of a series of
melanoma cell lines to MEK1/2 inhibitors in vitro. These authors
reported that cell lines with BRAF-activating mutations were much
more sensitive to MEK inhibitors in comparison to those with RAS
mutations. This finding was generalised to cancer cell lines derived
from different tissues, although thyroid cancer cell lines were not
included. These data suggest that expression of constitutively
activated BRAF uniquely predicts sensitivity to MEK inhibition
compared to tumours with RAS mutations, perhaps owing to RAS-
mediated activation of signalling molecules not in the linear
RAS–RAF cascade (Figure 1). Whether BRAF mutations uniquely
predict response to MEK inhibitors in thyroid cancer will need
further in vitro and in vivo study.
Clinical studies
Until recently, there were very few clinical trials available for
patients with iodine nonresponsive forms of thyroid cancer.
However, with the expanding development of kinase inhibitors and
the success of using a targeted approach to treating other forms of
cancer with well-defined genetic causes, such as chronic myelo-
genous leukaemia and gastrointestinal stromal tumours, thyroid
cancer has become an obvious target for drug development. As
described above, preclinical studies suggested that tyrosine kinase
inhibitors that also block RAF activation might be useful for
patients with thyroid cancer. Moreover, these studies suggested
broad degrees of activity in thyroid cancer cell lines independent
of BRAF V600E mutations due either to activity of the compounds
at alternative targets or activation of RAF kinases by other
oncogenes (or both).
Of the BRAF-targeted agents, Sorafenib has progressed to
approval by the United States Food and Drug Administration for
therapy of renal cell carcinoma and is under evaluation for
melanoma, thyroid cancer and other malignancies. In phase 1
studies, patients with metastatic solid cancers were treated with
different dosing schedules of Sorafenib and one partial response
in patients with PTC was reported (Strumberg et al, 2002). These
data, along with the logic of targeting RAF, RET and VEGF in
thyroid cancer therapy led to the development of several phase 2
studies of Sorafenib as a solitary agent for treatment-refractory
differentiated or anaplastic thyroid cancer that are ongoing or were
recently completed. Side effects of this agent include hypertension,
hand–foot syndrome, rash and fatigue that can be dose-related,
and in the case of the rash, may be associated with tumour
response to the compound (Strumberg et al, 2006).
It is of interest that Sorafenib is active against renal cell
carcinoma, a tumour that does not frequently have BRAF
mutations, suggesting that some of its clinical activity may be
directed against non-RAF targets. Sorafenib is being studied in
combination with cytotoxic chemotherapeutic agents, such as
doxorubicin in melanoma where, despite a high frequency of BRAF
mutations, this agent does not appear to be majorly biologically
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tested for activity in thyroid cancer in vitro or in vivo. It seems
likely that at least some of the effects of this agent in vivo are likely
to be due to inhibition of RET, KDR and/or PDGFR.
A preliminary analysis of 16 chemo-naı ¨ve patients (of 58 total
study participants) with progressive PTC treated with single-agent
Sorafenib (400mg twice daily) in a phase 2 study has revealed a
RECIST-determined partial response (430% reduction) in one of
16 patients, with minor responses (20–30% reduction) in 50%
over a mean follow up of 9.9 months (RT Kloos, personal
communication). The durability of those responses is variable,
with some patients progressing rapidly after initial responses over
several months and others developing disease stability for more
than 12 months. The final response analysis and the correlations
between response and tumour genotype and signalling inhibition
on biopsy samples are pending. However, based on these data, it
appears that Sorafenib alone will be unlikely to induce complete
remissions from thyroid cancer. These results compare favourably
to a recently reported phase 2 study of Sorafenib in patients with
melanoma in which the response rate was lower and the rate of
progression was higher (Eisen et al, 2006).
It is important to recognise that the precise mode of action for
Sorafenib in thyroid cancers is uncertain. This compound has a
number of potential therapeutic targets that may be responsible for
its clinical activity. Finally, as noted above, targeting MEK may
represent a more potent alternative for tumours with BRAF-
activating mutations (Solit et al, 2006).
SUMMARY
Activating mutations in the BRAF gene and constitutive signalling
through RAF kinases are common events in the development of
thyroid cancer. BRAF V600E mutations may be associated with
thyroid cancer progression, have been defined as thyroid
oncogenes experimentally, and may be, in part, responsible for
tumour dedifferentiation and loss of response to standard
therapies, such as TSH suppression and radioiodine. Because
patients who do not respond to these therapies have a poor
prognosis with no proven effective therapeutic options, they
represent an important population for the development of new
therapies. BRAF and its downstream signalling pathway represent
a potential therapeutic target that is being actively studied in
thyroid cancer. The studied compounds vary in their specificity for
RAF kinases, but have shown potential benefit in preclinical
studies and in early reports of clinical trials. Validating the actual
targets of these drugs in clinical trials and exploration of
combination therapies are important future goals to maximise
the potential utility of this approach for patients with progressive
thyroid cancer.
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